While All Eyes are on 340B Contract Pharmacy Battle, Federal Appeals Court Hears Arguments in Key Case Challenging HRSA’s Patient Definition

Genesis Health Care office sign and facility
A South Carolina health center's lawsuit, now before a federal appeals court, challenges one of of the 340B program's basic elements—the definition of a “patient” eligible to receive 340B drugs.

Part 1 of Two-Part Deep Dive into One of the Most Important and Contentious Areas of 340B Program

While much of the 340B community’s attention has been focused on the contract pharmacy suits winding through the federal court system, there

Read More »

340B Patient Definition Is at the Heart of Case Debated Before Federal Appeals Court

USCA Fourth Circuit court building
A federal appeals court in Richmond, Va., heard arguments last month in a case involving the legality of the 340B program definition of "patient."

Part 2 of a Two-Part Series About One of the Most Important and Contentious Areas of the 340B Program. Read Part 1 here.

An attorney for a South Carolina health center asked a federal appeals court in Richmond, Va., last

Read More »

340B ESP Makes Changes to Its Terms of Use that Entities Must Accept

screenshot of 340B ESP home page
A screen capture from 340B ESP's home page. The drug industry contractor that helps manufacturers implement 340B contract pharmacy restrictions yesterday updated its terms of use for 340B covered entities that decide to use its portal.

Second Sight Solutions, the drug industry contractor that collects 340B contract pharmacy claims data on manufacturers’ behalf through its 340B ESP portal, has revised the terms of use that covered entities must accept when they register to use the portal.

Read More »
Industry Insights Logo

340B and Value-Based Payment Keep Safety Net Doors Open

SPONSORED CONTENT

In recent years, the federal 340B drug discount program has grown in importance for safety net facilities. Covered entities are continuing to battle the effects of the COVID-19 pandemic which lead to uncertainties including provider and staffing shortages, impacts on 340B eligibility, and revenue shortfalls. The financial

Read More »

Influential 340B Lawmaker Upton Announces Retirement

Rep. Fred Upton speaks at a House hearing
U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, is retiring from Congress.

U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, announced on Tuesday he will not seek another term in Congress.

“Even the best of stories has a last chapter,”

Read More »

Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion

Institute for Clinical and Economic Review wordmark
Policymakers should consider narrowing the 340B orphan drug exemption, ICER said today in a new report.

The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential

Read More »

Illinois Legislature Passes 340B Anti-Discrimination Bill

Illinois state capitol building
Illinois lawmakers have passed legislation to forbid PBMs, third party payers, and Medicaid MCOs from discriminating against 340B covered entities and their contract pharmacies.

The Illinois legislature has voted to forbid pharmacy benefit managers, third party payers, and Medicaid managed care organizations from discriminating against 340B covered entities and their contract pharmacies.

At least three other states have passed similar legislation so far in

Read More »

340B INDUSTRY LEADER SPOTLIGHT

Nick Rebmann, CEO, Hudson Headwaters 340B

Nick Rebmann

Q: Where did you grow up?

I grew up in Collins, NY which is about 30 minutes south of Buffalo, NY.

Q: Where did you go to college/graduate school?

After graduating high school, I attended Albany College of Pharmacy and Health Sciences. This is a unique program that allows you to complete your Doctor of Pharmacy (Pharm. D)

Read More »

Exclusive: Gilead Responds to Health Center Group’s Criticism of its 340B Contract Pharmacy Policy

Gilead exterior office sign
Gilead told NACHC in a letter yesterday it is concerned about the group's criticism of the company's new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments.

Drug manufacturer Gilead told the National Association of Community Health Centers yesterday that NACHC’s condemnation last month of Gilead’s new conditions on 340B contract pharmacy pricing on its branded hepatitis C treatments “seem to represent a misunderstanding of this integrity

Read More »
Industry Insights Logo

Roundtable Discussion: 340B Drug Pricing Program: Recent Legislative Updates and Key Trends Impacting Hospitals, FQHCs and Other Designated Entities

SPONSORED CONTENT

The CPS 340B Solutions team is excited to host nationally recognized 340B industry thought leaders for a roundtable discussion about recent events, legislative updates, and key industry trends that impact all 340B Covered Entity designations. We hope that you will join us!

During

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live